|I'm sure this all sounds very esoteric to the non-specialist, and is obviously not certain to ensure at the company makes money, but the capabilities and biological responses Avacta are generating are truly remarkable and extremely valuable in their own right.|
|The following is not on Avacta's Events page. I did highlight this work back in March, but note it has been accepted for a poster presentation at the American College of Rheumatology Annual Meeting -
Session » Genetics, Genomics and Proteomics - Poster I
Date: Sunday, November 13, 2016
Meeting: 2016 ACR/ARHP Annual Meeting
ABSTRACT NUMBER: 59
Novel Agents for Blocking the Interaction of Immune Complexes with the Activatory FcγRIIIa Receptor
Conclusion: The results suggest that Adhirons can be developed to inhibit protein-protein interactions that were previously considered to be “undruggable”. Adhirons that inhibit the activatory FcγRIIIa (expressed on macrophages) but not the highly homologous FcγRIIIb (expressed on neutrophils), have been identified. This level of specificity has not been achieved using more conventional monoclonal antibody-based technology. Furthermore, the allosteric binders highlight a novel FcγRIIIa ‘hot spot’, which could be used in in silico-based Medicinal Chemistry design tools.
|Affimers are potentially a disruptive technology with a market valued in tens of billions of dollars. If they prove what the scientists continually seem able to confirm for now, eventually this disruptive technology could deliver telephone number revenues and profits.
Abcam has a market cap of £1,825M ... which within the limited confines of the antibody sphere is excellent. The Affimer market could be factors higher than antibodies because Affimers can remove some of the production issues associated with trying to generate a new antibody (e.g. high toxicity) - in theory, Affimers have the potential to replace existing antibodies, and fill all the gaps to boot.
Not at all blind to the fact this remains jam-tomorrow, for me it is one of the most exciting stocks to be in. It's a sensible sized portion of my portfolio, but I have invested just over £20k so far and will continue to build as the story, or confirmations and milestones, keep developing.
The excitement and optimism when you meet the senior team is borderline infectious - both the scientists and businessmen.|
|I will leave you until the half year with one last thought. Six years ago it was on a market cap of 10million loosing one million a year. After several rights issues it is now on a market cap of 60 million loosing nearly 5million a year when in theory on that market cap it should be making 5million a year.|
|Poacher...I am fully cognisant of the past, but whilst mindful of such, Avacta has evoloved into a somewhat different business. So with respect, let's end this discussion for now because you are looking backwards (glass half empty) and I am looking fowards (glass half full). Lets see how things sit at the half year (31st Jan) and full year (31st July).|
|Wan 2011 What is the difference five years later no profits just pie in the sky. All...Some will recall that Avacta entered into an agreement with EV (Medical Screening) Limited (“EV”) for the exclusive worldwide rights to Avacta’s laser based breath diagnostics technology.
At the time there was scant information on EV, however, that has now changed. EV (Medical Screening) has changed its name and its directors.
If you want a bit more information, put the name Oxford Medical Diagnostics into the Companies House website search facility and then click the highlighted company reg no –
Then click “order information on this company” to arrive at a list of documents where you will note the various changes and where you can order any of the documents.
In short, EV (Medical Screening) has become Oxford Medical Diagnostics –
The Avacta deal is reported here -
Some may even recall that in 2008 Avacta actually bought the Oxford University spin out company, Oxford Medical Diagnostics –
AVACTA ACQUIRES OXFORD MEDICAL DIAGNOSTICS
So I was interested to learn that it was apparently not just a licensing agreement –
EV (Medical Screening) acquired the former Oxford Medical Diagnostics business from Avacta in August 2010 –
Oxford Medical Diagnostics Limited was formed in August 2010 as the result of the merger of three entities:|
|Last five years turnover figures:-
Not only for various reasons has turnover stagnated but every year without exception expenses have gone up mainly staff numbers and wages.|
|You have told us on numerous occasions over the past 6 years that this is going to be successful only for the management to once again let you down. Show me growth in turnover and I will believe it until then it is just pie in the sky.|
|Poacher...Putting Animal Health aside, of course it is to do with whether Affimers work....hence the various Affimer evaluations that are underway....if you take the time to listen to the presentation you will detect a new level of optimism/confidence from the management.
From my perspective, Avacta's management appear to be making very good progress, with important foundations for the Affimer technology being established and although there is more work to be done, the building blocks looks like they will be on order soon!|
|The directors have never delivered on there promises. Turnover last year up £360,000
to £2.17 million. Losses down £240,000 to £4.65 million. It now needs only to turn over £8,000,000 million just to break even. Every year expenses go up and up and up. The only thing that keeps saving it is a rights issue which seems to happen every 18months. It is not to do with whether Affirmers work or not it is down to bad management and lack of controls. This will never be a successful company in my opinion. It is just pie in the sky.|
|apologies if already posted...
|Poacher...One assumes then that you did not watch the Presenation and in any regard you certainly don't appreciate what has already been achieved by the current management, and apparently nor will you be by any further technology validation or value inflection points.
Given the level of third party 'commercial' interest and the significant number of Affimer technology evaluations underway, Management are optimistic (confident) that deals will be signed in the current fiscal year. You might not get instant profitability from some of these possibilities, but if any do come to fruition, without doubt they will create both value and attract further commercial interest.....all of which will in turn create value.
In short, we could hit finncaps price target of £2 and still not be profitable, but still have much more to go for in terms of further value creation.|
|Are you suggesting that the 3rd party agreements will never deliver the milestone payments that they might?
That Affimers effectively "don't work" and so will be of no commercial interest?
and that the crown jewels of an internal therapeutic is never likely too/
I assume you have a large short position? or should have if that's what you firmly believe.|
|Shareholders want it profitable which is impossible with the current management.|
|A week ago I said that "It will be interesting to see what impact Phillpe Cotrel (Chief Commercial Officer) has had since joining from Abcam in January." His contribution in the webcast is informative in this regard and clearly he his making important strides, if not step changes in the three target areas.
It was also interesting to note several, not insignificant, development milestone achieved.
The confidence now eminating from Avacta is palpable!|
|Avacta Preliminary Results Webcast is now available -
|Avacta events page list the next event as PEGS Europe.
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. Over the last three years, participation at PEGS Europe has grown by more than 60%, and this year will be the largest ever. With a more-focused technical program, and double the coverage of the most popular PEGS topics
Avacta events page states the following -
Monday 31 October 2016
We are exhibiting at PEGS Europe
To be more specific and for those interested;
2 Posters -
Avacta Life Sciences - Generation and Formatting of Affimer Biotherapeutics for the Inhibition of the PD-L1/PD-1 Pathway
Avacta Life Sciences - Affimers - Next Generation Affinity Tools
One presentation -
Cambridge Healthtech Institute’s Inaugural
Novel Immunotherapy Strategies
Exciting Developments with Promise in the Clinic
Investigators who have believed in the potential of immunotherapy for years are finally being rewarded. Progress is being made with many different approaches, and evidence that they work is being seen in the clinic. We live in exciting times.
This conference track will include case studies on checkpoint inhibitors, CAR-T cells and other approaches, and will focus on the challenges encountered and, in many cases, overcome. Of particular interest is the product engineering, and the mode of action together with the background immunology. Particular challenges with immunotherapy are to do with safety, GMP manufacture and with regulatory approval.
TUESDAY 1 NOVEMBER
12:20 Cancer Biotherapeutics - Affimers: A Novel Scaffold for Biotherapeutics
Basran_AmrikAmrik Basran, Ph.D., CSO, Therapeutics, Avacta Life Sciences
Affimers® are a new protein scaffold with great potential for the generation of biotherapeutics. Based on the protease inhibitor Stefin A, large diverse libraries have been created by engineering in peptide loops into the scaffold backbone. Using phage display, we have identified competitive binders to a ranage of targets, including the immune check point, PD-L1. We have shown that the scaffold is amenable to being engineered with a range of half-life extension technologies.
|Latest Hardman note, with again more interesting details provided -
17th October 2016
Great strides towards strategic goals
|wan - absolutely not. Without my sensible head, this would be one of very few, if not my sole investment the potential is so great.|
|WWW.ft.com has a forecast of £1.60. Mind you, it's been that level for a while.|
|The Drewster...Are we to assume then that you are less optimistic now?
A lot has indeed changed in terms of development milestones, the management team and a respected Scientific Advisory Board installed, not to mention for the first time, separate Non-executive Chairman commentary, so I feel the context around the commentary has also changed.
Apparently Finncap has now set a ‘CorporateR17; rating on shares of Avacta Group PLC with a price target of 200p.|
|Still jam-tomorrow, which will put many off.
Still huge potential.
Many scarred investors have experience of "science" (technology or bio) companies led by scientists, and very few have happy endings. The strengthening of the board and advisors over the last couple of years could just make this one such investment.|
|There is some interesting commentary within the Results, but at the risk of repeating something that everyone can read, there was a statement that appears to be quite significant "We have strengthened our belief that Affimers have the potential to become an important new class of biological drug that could eventually rival antibodies." With a highly regarded Scientific Advisory Board in place since April, one assumes there is some weight of opinion behind statements like that.|
|More detail provided, along with an optimistic outlook statement.
As a Board, we are extremely optimistic about 2017 and beyond as we look to progress our Affimer therapeutic programmes and commercialise the Affimer research and diagnostic reagents with clinical and commercial partners.
Avacta Group PLC - AVCT
Prelim Results for the Year Ended 31 July 2016
Released 07:00 17-Oct-2016